Setting the Scene: What brought you here today?

• Which of these most closely describes the trigger that brought you to explore formulary solutions now? Options: Three specialty launches in one therapeutic class, Projected >5% pharmacy budget increase, Regulatory pressure or audit risk, P&T committee bandwidth constraints, Other
• Who on your team is most immediately responsible for addressing this trigger? Options: Pharmacy Director, Chief Medical Officer/CMO, VP of Benefits, Head of Clinical Operations, Other
• In a sentence, what outcome would make this effort worth your time?
• How urgent is a solution on a scale from operational housekeeping to immediate regulatory or budget crisis? Options: Immediate (weeks), Short-term (1–3 months), Quarterly (3–6 months), Longer-term (>6 months)

This Budget Shock Feels Real — How Bad Is It?

• If we assume three new specialty launches move to open access, how would that change your pharmacy spend and reserve assumptions? Options: Add <3% to budget, Add 3–6% to budget, Add 6–10% to budget, Add >10% to budget, Unsure / need modeling
• Tell us about the specific budgetary or operational consequences you fear if clinical criteria aren't in place for these launches.
• Which of these downstream impacts worries you most? Options: Provider complaints/appeals, State regulator scrutiny, Member churn, Catastrophic budget variance, Operational overload
• How have past rapid drug launches or formulary changes affected your team’s morale or risk appetite?

Who's In The Room — And Who’s Quietly Influencing Decisions?

• Who are the decision-makers and approvers for formulary changes in practice (not just on paper)? Options: Pharmacy Director, CMO/Medical Director, VP of Benefits, Legal/Compliance, Finance, External consultants
• Which stakeholder roles tend to slow decisions down and why?
• How aligned are clinical, financial, and compliance stakeholders on what 'acceptable risk' looks like? Options: Completely aligned, Mostly aligned with some debates, Frequently misaligned, Totally misaligned/fragmented
• Are there external stakeholders (state regulators, client groups, large providers) who must be engaged before a P&T vote? Who are they?
• What timeline pressures do decision-makers face (e.g., statutory notification windows, contract renewal dates)? Options: Immutable statutory deadlines, Quarterly committee cycles, Renewal-driven windows, Flexible but constrained by operations

Where the Process Trips Up (and How It Feels)

• What are the recurring failure modes when you push a formulary change from committee into claims? Options: Mapping errors, Criteria mismatch, Publication delays, Claims engine rejects, Member communication failures, Other
• Describe a recent example where a formulary change produced an unexpected claim or member outcome. What happened?
• How do your current P&T workflows capture rationale, evidence, and dissenting opinions today? Options: Email + spreadsheets, Homegrown database, Paper/minutes only, Partial automation, Other
• When mistakes happen, how long does it typically take to detect and remediate them? Options: Same day, 1–7 days, 1–4 weeks, Months
• How does it feel to your team when a change produces provider pushback or regulator questions?

What 'Good' Actually Looks Like to You

• If the formulary process were running ideally, what are the first three things you would notice that are different?
• Which success signals matter most to your executive sponsors? Options: Reduced net pharmacy spend, NCQA-aligned P&T process, Fewer appeals/complaints, Faster time-to-coverage decisions, Operational cost savings
• What clinical outcomes or utilization metrics would you expect to monitor after a specialty launch is governed by criteria? Options: Adherence rates, Appropriate initiation rates, Avoided hospitalizations, Utilization by provider type, Other
• What tradeoffs would you accept (e.g., slightly slower approvals for stronger criteria) and which are off the table?
• Which regulatory or accreditation standards are non-negotiable in your view (NCQA elements, state statutes, Medicare rules)? Options: NCQA P&T standards, State-specific coverage laws, Medicare Part D rules, Commercial contract terms, Other

Data Reality Check: How Trustworthy Is Your Source of Truth?

• Which systems currently hold your definitive formulary and clinical criteria data? Options: Claims adjudication engine, Internal formulary spreadsheet, Clinical content DB, Third-party vendor, Other
• How complete and current is your drug database compared with industry-standard sources? Options: Fully current, Mostly current with gaps, Outdated in key areas, We don't track currency
• Do you currently have automated publishing into claims, and if so, how often does it occur? Options: Real-time, Daily, Weekly, Manual batch, No automated publishing
• Which data handoffs worry you most during migration or cutover? Options: Criteria templates, Tier mappings, NDC/HCPCS mapping, Prior authorization logic, Member/subscriber mapping
• Tell us about a past data migration that went well or poorly and what you learned.

How Decisions Actually Get Made (Behind Closed Doors)

• How often does your P&T committee meet, and how many cases are reviewed per meeting? Options: Weekly, Biweekly, Monthly, Quarterly, Ad hoc
• What percent of reviews include formal economic modeling versus clinical only? Options: >75% include modeling, 50–75%, 25–50%, <25% or none, Unsure
• How independent is clinical decision-making from rebate or contracting discussions? Options: Completely independent, Mostly independent with occasional overlap, Frequent overlap, Not independent / unclear
• When a new specialty drug arrives, how long does it take from first review to committee vote in practice? Options: <2 weeks, 2–4 weeks, 1–3 months, >3 months
• Describe how dissenting opinions are documented and how they influence final recommendations.

Cutover Nightmare vs Dream: What Keeps You Up at Night?

• Which of the following cutover risks would be catastrophic to you? Options: Claims mismatches causing wrong member payments, Incorrect clinical criteria approving inappropriate use, Delayed provider notifications triggering complaints, Regulatory notice of noncompliance, Data loss during migration
• What rollback or contingency capabilities do you require before you can sign off on cutover? Options: Instant rollback to prior formulary, Parallel run with shadow claims, Manual override by operations, Executive sign-off triggers, Other
• What internal approvals must be in place before a production change (technical, legal, clinical, executive)? Options: Technical/IT, Legal/Compliance, Clinical/Medical Director, Executive sponsor, Operations
• How would you like to validate cutover readiness—what specific tests or criteria would make you comfortable?

Timing, Governance, and What Success Feels Like to Your Leadership

• What deadline would be a dealbreaker for you (statutory, renewal, or internal mandate)? Options: Statutory deadline, Contract renewal date, Next P&T cycle, No hard deadline
• How frequently do you want governance check-ins during discovery and deployment? Options: Weekly, Biweekly, Monthly, Ad hoc as needed
• Who should be the single owner on your side for operational coordination?
• What acceptance criteria would your executive sponsor require to sign final mutual commit? Options: Validated cost model, NCQA-aligned P&T artifacts, Successful claim simulations, Data migration confirmation, All of the above
• How would you measure success at 30, 90, and 180 days post-deployment?

What Would Make You Say Yes — and What Would Make You Walk Away?

• Which commercial terms or guarantees would reduce your risk perception most? Options: Service credits, Fixed scope & price for migration, Performance SLAs, Regulatory indemnity, Other
• What operational commitments from us (training, runbooks, shadow period) would be table stakes for you? Options: Comprehensive training, Dedicated implementation lead, 30-day shadow operations, Detailed runbooks and rollback plans, Ongoing post-launch support
• What would be a non-negotiable red flag in any proposed solution? Options: Lack of claims integration, No ability to model cost impact, Criteria templates not NCQA-aligned, Vendor manages rebate-influenced tiers, Limited audit trail
• Realistically, what timeline would you be willing to commit to for a full implementation (data migration through go-live)? Options: <3 months, 3–6 months, 6–9 months, >9 months
• What next step would feel like progress to you after this discovery (demo, cost model, pilot, contract draft)? Options: Live demo with committee case, Customized cost and utilization model, Pilot on one therapeutic area, Draft commercial term sheet, Other

Quick Facts and Artifacts We Should Collect

• Which artifacts can you share to help us model impact and readiness (select all that apply)? Options: Current formulary CSV or export, Recent P&T minutes, Claims engine schema details, Historical utilization and spend by drug, Regulatory correspondence
• Who should receive our follow-up materials and the modeled scenarios? Options: Pharmacy Director, CMO/Medical Director, VP of Benefits, IT Lead, Legal/Compliance
• Is there any internal stakeholder we should avoid contacting without prior approval? Options: Yes — specify in comments, No
• Any additional context, concerns, or stories you want us to know before we prepare a tailored proposal?

Starting Together: A quick snapshot of who you are and why we're here

• Who from your team should we be engaging directly as we map your current state? Options: Pharmacy Director, Chief Medical Officer, VP of Benefits, Formulary Manager, IT/Integration Lead, Compliance/Legal, Other (please name), Prefer not to say
• What single event or trigger led you to request a Current State Mapping right now? Options: Three specialty launches in one category, Projected pharmacy budget spike, Regulatory scrutiny or provider complaints, Upcoming P&T committee vote, Audit or NCQA readiness concern, Other (please describe)
• How soon do you need a baseline assessment and recommendations that the P&T committee can act on? Options: Within 2 weeks, Within 1 month, 1–3 months, 3–6 months, Timeline unclear
• In one sentence: how do you currently record, approve, and publish formulary changes today?
• Who owns the day-to-day execution of formulary updates (names/roles) and who is the final approver for P&T recommendations?

What’s quietly costing you money (and credibility)?

• If we don’t change anything, how much could those three specialty launches increase your pharmacy spend in 12 months? Options: < 2% of pharmacy budget, 2–5%, 6–9%, 10–15%, > 15%, Unsure / need modeling
• Which of the following outcomes worries you most about leaving launches unmanaged? Options: Budget overrun, Provider backlash/complaints, State regulatory action, Member access inequities, NCQA or accreditation impact, Other
• Have you experienced provider complaints, appeals, or regulator inquiries tied to formulary enforcement in the last 24 months? Tell us what happened.
• How would you describe the emotional pressure this creates for your formulary or benefits team? Options: Constant high stress, Frequent pressure moments, Intermittent stress, Manageable / low
• Which stakeholders will judge success most harshly if a formulary decision causes downstream problems? Options: VP Benefits/Finance, Pharmacy Director, Chief Medical Officer, Provider groups, State regulators, Members/patients, Other

Walk us through the journey: from a new drug on the market to claims enforcement—where does it snag?

• When a new drug arrives, what are the exact steps you follow from clinical review to publication in the claims system? Please describe roles and timing.
• Which tools or systems do you use to manage these steps today? Options: Spreadsheets, Home-grown database, Commercial formulary platform, EHR-integrated tool, Claims vendor console, Paper / email workflow, Other (please name)
• How long, on average, between a P&T decision and the change being enforceable at claims adjudication? Options: Same day, 1–3 business days, 4–10 business days, 2–4 weeks, Longer / variable, Don't know
• What are the most common points where the handoff fails (examples: version drift, mapping errors, update scheduling)? Provide recent examples if possible.
• Do you maintain an auditable trail that links evidence, committee minutes, decision rationale, and the specific claim-rule implementation? If not, what’s missing? Options: Complete audit trail, Partial (some documents linked), Minimal / manual notes only, None

Where clinical rigor meets real-world constraints: are you compromising one for the other?

• How independent is your P&T process from commercial/rebate discussions today? Options: Completely independent, Mostly independent with occasional overlap, Some overlap/unclear boundaries, Influenced by commercial considerations, Not sure
• How do you evaluate clinical evidence for new specialty launches—who reviews, what sources do you require, and how do you document their conclusions?
• How often do you benchmark formulary recommendations against NCQA expectations or external clinical guidelines? Options: Continuously (monthly), Quarterly, At each major review, Only when preparing for NCQA, Rarely/Never
• When push comes to shove, which do you prioritize: speed to implement a cost-saving policy, or waiting for more clinical certainty? Tell us how that decision gets made. Options: Speed first, Clinical certainty first, Case-by-case, No clear process
• What internal checks or sign-offs would make you confident that a new coverage rule is clinically defensible and regulator-ready?

Integration Points That Break Things (and how you detect them)

• Which vendor systems must be updated for a formulary change to fully take effect (select all that apply)? Options: Claims adjudication engine, Pharmacy claims/pricing system, EHR/Provider portals, Prior authorization platform, PBM clinical rules engine, Member benefits portal, Other (please specify)
• Who is accountable for the technical handoff to each system (roles and SLA expectations)?
• How do you currently validate mappings and lookups between formulary codes and claims/NDM fields before cutover? Options: Automated mapping tests, Manual spot checks, End-to-end claim simulations, No formal validation, Other
• What test coverage do you require before accepting a migration—e.g., percentage of rules simulated, sample claim volumes, or list of high-risk scenarios?
• How do you detect and alert on live discrepancies after a change is published (time to detection, monitoring tools, and escalation path)?

When rules fail: concrete failure modes and their real costs

• Tell us about the most recent time a formulary change caused incorrect claims handling—what was the root cause and outcome?
• What financial or member-facing impacts did that incident create (select all that apply)? Options: Overpayments, Underpayments, Member access interruption, Provider appeals, Regulatory inquiry, Reputational damage, Other
• How long did it take to detect and fully remediate the issue? Options: < 24 hours, 1–3 days, 4–10 days, Weeks, Still unresolved / recurring
• What recurring root causes do you see across incidents (data mapping errors, misconfigured criteria, timing windows, manual overrides, other)?
• What would have prevented the incident you described—additional tests, clearer ownership, rollback plan, or something else? Options: More comprehensive tests, Dedicated owner for deployment, Automated rollback capability, Better documentation/audit trail, Faster monitoring/alerts, Other

If everything went right: painting the outcome you can sign off on

• What are the top three measurable success signals you would need to see post-deployment (financial, clinical, operational)?
• What acceptable tradeoffs would you tolerate (e.g., delayed non-critical updates for guaranteed accuracy) and what tradeoffs are non-negotiable?
• Which NCQA or regulatory criteria must be demonstrably met before you call the deployment acceptable? Options: Evidence-based P&T documentation, Timely publication to claims, Audit trail for decisions, Member appeals processes, Other (specify)
• How quickly would you expect to see value (reduced spend, fewer appeals, smoother P&T cycles) after go-live? Options: Within 1 month, 1–3 months, 3–6 months, 6–12 months, Unsure
• Who must sign off on 'success'—list the titles/roles and what each cares most about.

First small step: what would make you say yes to exploring a solution?

• Which decision criteria are non-negotiable for you when selecting a formulary management partner/platform? Options: Clinical independence of P&T, Robust audit trail, Seamless claims integration, Fast time-to-enforce, NCQA alignment, Clear rollback/rollback plan, Transparent commercial terms, Other
• What would you need to see in a pilot or proof-of-concept to feel confident (scope, sample scenarios, duration)?
• Which integrations would we need to demonstrate first to de-risk your deployment (select up to three)? Options: Claims adjudication engine, Prior authorization platform, Member portal publish, EHR/provider portal, Clinical evidence library, Other
• What risk mitigations would make you comfortable starting (examples: parallel run, escrow rollback, 3rd-party attestations)? Options: Parallel operation / shadow mode, Automated rollback mechanism, Granular acceptance checklist, Staged cutover by product class, Third-party audit, Other
• Realistically, who needs to be involved in the next meeting to move forward (roles), and what date range works for scheduling that conversation?

Quick Grounding — Who's at the Table?

• Who will be the primary point-of-contact and day-to-day owner for the deployment on your side?
• Which stakeholders must sign off for go/no-go at cutover (titles/roles, not names)? Options: Pharmacy Director, Chief Medical Officer, VP of Benefits, IT/Integration Lead, Compliance/Legal, Finance, Other
• What is your target calendar window for cutover and any immovable date constraints (e.g., regulatory deadlines, benefits renewal)? Options: Within 30 days, 30–60 days, 61–90 days, 3–6 months, Other/Not decided
• Which systems must be synchronized at cutover (claims adjudication, ePA, EHR feeds, data warehouse, other)? Please list systems and owners.
• Who on your team will be available during the cutover window for rapid decisions (names/roles and typical availability hours)?

If Cutover Broke Tomorrow, What Would Break First?

• Which formulary-to-claims discrepancies have caused the largest real-world issues in prior changes (patient denials, incorrect tiers, reimbursement errors)?
• How would a claims enforcement error show up operationally—volume of impacted members, speed of provider complaints, regulatory escalations, or financial leakage? Options: Member denials, Provider appeals, Increased urgent approvals, Regulatory complaint, Noticeable financial variance, Other
• Roughly how much financial exposure (annualized pharmacy spend %) could a failed specialty cutover create for you? Options: <1%, 1–3%, 3–6%, 6–10%, >10%, Unsure
• Tell us about a past deployment or formulary change that didn’t go as planned—what failed, how long did it take to recover, and how did it feel to your team?
• Who would be escalated to within your organization if a major discrepancy occurred on day one (roles and expected response times)?

Where Does Your Data Hide Its Surprises?

• How confident are you that your current master formulary extract is the single source of truth for tiers, criteria, and NDC mappings? Options: Very confident, Somewhat confident, Not confident, We don’t have a single source
• Which file extracts will we rely on for migration and nightly syncs (format, frequency, sending system)?
• Which identifier standards do you use today for claims/formulary mapping (NDC, GPI, RxNorm, proprietary IDs)? Options: NDC, GPI, RxNorm, Proprietary IDs, Mixed/Other
• Where have you historically seen the most mapping exceptions—therapeutic equivalents, biosimilars, legacy codes, or custom local codes? Options: Therapeutic equivalents, Biosimilars, Legacy codes, Custom local codes, Other
• Give an example of a single data issue you’d call a deployment ‘showstopper’—what is it and how often does it occur?
• Are there any regulatory or state-specific formulary fields (e.g., prior authorization codes, reporting flags) we must preserve exactly during migration? Options: Yes—list them, No, Unsure

What Would You Do If We Had to Roll Back?

• Do you currently have a formal rollback plan template for formulary/claims cutovers, or would you expect us to provide one? Options: We have a template, We expect vendor to provide, We’ll collaborate to create one, No rollback plan exists
• What are the non-negotiable criteria that would trigger an immediate rollback (quantified thresholds if possible)?
• How long is an acceptable rollback window—hours, days—before members/operations suffer irreparable harm? Options: <4 hours, 4–12 hours, 12–24 hours, 1–3 days, >3 days, Unsure
• If a rollback were executed, what reconciliation and reporting would you require to feel confident the system is restored?
• Who must authorize a rollback and who executes it (roles and contact methods)?

How Fast Do Approvals Come When Seconds Matter?

• If a regulatory agency raised a compliance concern during cutover, how quickly can your legal/compliance team review and respond? Options: Within 1 hour, Same day, 1–3 days, Longer than 3 days, Unsure
• Do you have standing governance meetings (e.g., emergency P&T or leadership) that can be convened on short notice during deployment? Options: Yes—can convene within hours, Yes—within a day, No, but can escalate, No standing process
• Which approvals are required before we push criteria changes to claims (commercial signoff, clinical signoff, legal, IT)? Options: Clinical/P&T, Pharmacy Ops, IT/Integration, Legal/Compliance, Finance, Other
• Describe any external parties (PBM vendors, clearinghouses, state agencies) whose approvals or acknowledgements are required pre- or post-cutover.
• How do you prefer approvals be captured and archived (audit log, signed PDF, recorded meeting notes)? Options: Audit log, Signed PDF, Recorded meeting notes, Email trail, Other

How Will You Know We’re Safe at Cutover?

• What acceptance tests are non-negotiable for you before we declare success (claim simulations, P&T dry-run, member-facing publishing checks)? Options: Claim simulations, P&T dry-run, Member communication validation, EHR/ePA sync test, Reporting validation, Other
• Can you share existing test cases or scenarios that reflect the highest-risk member journeys we should simulate?
• What performance or accuracy thresholds will you use to accept the deployment (e.g., <0.1% claim mismatch, 100% criteria enforcement for test scripts)?
• Who signs the final validation checklist and what artifacts do they require (test logs, simulation reports, executive summary)?
• Would you prefer a progressive cutover (phased cohorts) or a big-bang approach—and why? Options: Phased cohorts, Big-bang, Hybrid, Undecided

What Would Keep You Up at Night After Deployment?

• Which post-cutover metrics would you monitor closely for the first 30 days (appeals volume, unexpected spend, claim denial rate, provider complaints)? Options: Appeals volume, Unexpected spend, Claim denial rate, Provider complaints, Member inbound calls, Other
• How do you expect incident response to work post-deployment—SLAs, escalation path, regular check-ins?
• What monitoring dashboards or reports do you need in real time to feel comfortable (itemize required views)?
• How long would you want vendor-led on-call support post-deployment before transitioning to steady-state support? Options: 1 week, 2 weeks, 1 month, 3 months, Ongoing as needed
• If an unexpected clinical or financial trend appears post-cutover, what decision rights do you retain and how quickly would you want joint remediation meetings?

Agreeing the First Sprint — Clear, Measured, and Human

• What three things must be delivered in our first two-week sprint to build your confidence in this deployment?
• Which raw artifacts can you share immediately to accelerate kickoff (sample extracts, mapping tables, test cases, committee minutes)? Options: Sample extracts, Mapping tables, Test cases, Committee minutes, None available yet
• Who on your team should be invited to weekly sprint reviews and what decisions can they make autonomously?
• What would feel like an early warning that we should slow down and expand testing before cutover?
• Finally, what is your single biggest hope for this deployment—and one realistic fear we should plan for right now?

Quick Snapshot: Who's in the Room?

• Who from your organization will actively participate in formulary decisions for the next three specialty launches? Options: Pharmacy Director, Chief Medical Officer, VP of Benefits, P&T Committee Chair, Pharmacy Operations Manager, IT/Integration Lead, Legal/Compliance, Vendor/PBM Representative, Other
• What's the immediate trigger that pushed this review onto the agenda right now? Options: Multiple specialty launches, Budget threshold exceeded, Upcoming P&T vote, Regulatory/state inquiry, Contract renewal or RFP, Provider/member complaints, Other
• Roughly how many members/lives does this formulary cover and what is the approximate annual pharmacy spend?
• Which timeline best describes when you need coverage decisions and claims cutover completed? Options: Within 2 weeks, 2–4 weeks, 1–3 months, 3–6 months, Longer than 6 months
• Are there any state reporting windows, regulatory deadlines, or upcoming audits that constrain timing? Options: Yes — specific deadline(s) exist, No immediate deadlines, Unsure / need to check

If We Don’t Act, What Breaks First?

• How likely is it that adding the three specialty launches without evidence-based controls will push you past your pharmacy budget threshold or trigger regulatory action? Options: Almost certain, High risk, Possible, Unlikely, Not sure
• Estimate the projected budget impact if no controls are added (choose the range closest to your scenario). Options: <2% uplift, 2–5% uplift, 5–8% uplift, 8–12% uplift, >12% uplift, Unsure / need modeling
• Which stakeholder(s) would escalate first if budget or access problems occur? Options: Pharmacy Director, VP of Benefits, CFO, Plan Sponsor, Medical Director/CMO, P&T Chair, Regulatory/Compliance, Other
• Have you had provider complaints, state inquiries, or member harm related to formulary changes in the past 24 months? If yes, please describe one example and its outcome.
• What is the worst-case operational ripple you expect if a discrepancy reaches claims adjudication at cutover? Options: Widespread denials and appeals, Emergency rollback and manual overrides, State regulatory scrutiny, Significant member/provider communications, Contractual penalties, Other

Where Paperwork and Practice Tend to Drift

• How confident are you that a formulary change captured in spreadsheets or meeting minutes will be enforced identically in claims at cutover? Options: Completely confident, Mostly confident, Some doubt, Not confident, We don’t currently synchronize
• Describe how a typical formulary review is documented and who is responsible for converting that decision into operational logic.
• What is your P&T cadence and average case volume per meeting? Options: Weekly (high volume), Biweekly, Monthly, Quarterly (low volume), Ad hoc / irregular
• Which systems currently act as authoritative sources of formulary and criteria (select all that apply)? Options: In-house claims engine, Third-party PBM system, Spreadsheets / Docs, Clinical decision support tool, Document management platform, Other
• How often have you discovered misalignments between published formulary and live claims enforcement? Please provide a recent example if possible.

What’s the Real Human Cost?

• Which reaction worries you most if controls fail — angry providers, denied members, or budget owners imposing blunt restrictions? Options: Angry providers, Denied members, Budget owners imposing blunt restrictions, Regulatory action, All of the above, Other
• Tell us about a recent incident where a formulary decision caused provider friction, member harm, or public scrutiny. What was the aftermath?
• How do such incidents affect internal trust in the formulary team and their recommendations? Options: Significantly erodes trust, Creates temporary friction, Little impact, Strengthens scrutiny but trust remains, Unsure
• Which reputational, contractual, or financial penalties could realistically materialize if enforcement fails at cutover? Options: State audit / sanctions, NCQA noncompliance findings, Contract penalties, Member litigation, Provider network disruption, Other
• What’s your current escalation path when a member is incorrectly denied on a high-cost specialty drug?

If We Could Snap Our Fingers, What Would 'Good' Feel Like?

• Imagine your P&T workflow always produced defensible, NCQA-ready decisions that flowed to claims without error — what operational difference would you notice first?
• Which success signals would make leadership say ‘this platform worked’ after the first 90 days? Options: Budget variance within target (specify), Fewer provider complaints, No production enforcement errors at cutover, Faster P&T review cycle, NCQA audit readiness, Reduced manual overrides
• Which tradeoffs are acceptable when balancing access, budget, and administrative burden? Options: Strict clinical controls with higher admin effort, Moderate controls with balanced admin, Favor access with higher budget risk, Case-by-case exceptions rather than broad controls, Depends by therapy class
• Which metrics should we include in a short pilot to prove value (pick up to five)? Options: Claims enforcement accuracy, Budget impact modeling, Provider appeal rate, Time-to-decision for P&T, Number of manual overrides, Member satisfaction/NPS, Audit trail completeness
• What’s the minimum time window you’d accept to demonstrate pilot success before scaling? Options: 2–4 weeks, 4–8 weeks, 8–12 weeks, Quarterly, Other

Where Decision-Making Could Be Influenced (But Shouldn’t)

• How confident are you that formulary decisions today are insulated from commercial or rebate influence? Options: Completely insulated, Mostly insulated, Some influence present, Significant influence present, Unsure
• Who attends P&T meetings and who is deliberately excluded to protect clinical integrity?
• Do you currently maintain documented firewalls or SOPs separating clinical review from contracting? If so, please summarize.
• Have any past formulary decisions been questioned for commercial bias? If yes, describe the situation and how it was resolved.
• Would visibility into time-stamped evidence logs, reviewer notes, and audit trails materially affect stakeholder confidence? Options: Yes — critical, Helpful but not required, No impact, Unsure

What Integration Nightmares Should We Prevent?

• If a migration error produced a widespread formulary mismatch at cutover, how quickly would you need to detect and roll back to avoid major harm? Options: Within minutes, Within hours, Same business day, 48 hours, Longer
• Which claims adjudication engines, pharmacy systems, or interfaces must we integrate with for a successful cutover? (select all that apply) Options: In-house claims engine (specify), Third-party PBM adjudicator, EHR/Provider-facing portal, Pharmacy dispensing systems, Clinical decision support, Other
• Do you have test and sandbox environments for end-to-end claims simulation, and who owns them? Options: Yes — full sandbox available, Partial test environments, No dedicated test env, Unsure / need to check
• What specific data extracts, mapping rules, and code lists can you provide (e.g., NDCs, tier codes, criteria logic)?
• Describe a past integration or timing constraint that delayed propagation of formulary changes into production and how you worked around it.

Who Owns What When It Counts?

• When the P&T committee finalizes a vote, who owns the operational translation into claims logic and publication? Options: Pharmacy Operations, IT/Integration, PBM/vendor, Clinical/formulary team, Shared responsibility, Other
• Who will be the designated owners for acceptance testing, rollback authorization, and governance sign-off during deployment?
• What approval cadence and format does your governance prefer for changes that affect claims enforcement? Options: Weekly governance meeting, Ad hoc sign-off via email, Automated workflow with countersignatures, Monthly steering committee, Other
• What incident response SLA do you require during deployment and early production? Options: 1 hour, 4 hours, Same business day, 48 hours, Custom SLA
• Who are the commercial/legal owners we must engage to finalize mutual commitments and contracts?

Are You Ready to Try a Better Way?

• How open is your executive leadership to piloting a formulary management platform that enforces criteria into claims and provides NCQA-aligned auditability? Options: Very open, Somewhat open, Neutral / needs convincing, Not open, Unsure
• Which pilot model would you prefer to validate safety and value? Options: Parallel run with live claims logging, Simulated claims testing only, Staged live pilot with rollback controls, Hybrid (simulation then live), Other
• What would you require us to provide before greenlighting a pilot (select all that apply)? Options: Gap analysis of current formulary, Technical integration spec, Pilot success criteria and metrics, Security/compliance documentation, Commercial terms, Other
• Who should sit on a pilot steering committee from your side? Options: Pharmacy Director, Medical Director/CMO, IT/Integration Lead, P&T Chair, VP Benefits, Compliance/Legal, Operations Manager, Other
• What is the single largest barrier to starting a pilot within the next 30–90 days? Options: Data access issues, Budget/contracting, Leadership approval, Technical integration readiness, Staff bandwidth, Other

Next Steps — Small Bets That Build Confidence

• If we left this session with one tangible commitment, what single next step would move the needle fastest for you?
• Which stakeholder(s) must sign off on that next step? Options: Pharmacy Director, VP Benefits, CMO/Medical Director, P&T Chair, IT Lead, Legal/Compliance, Other
• What timing works best for a technical discovery session to map data extracts, test environments, and integration milestones? Options: Next week, Within 2 weeks, 2–4 weeks, 1–2 months, No timeline yet
• Which artifacts would be most helpful for your team ahead of that session? Options: Detailed gap analysis, Sample mapping templates, Pilot plan with metrics, Security/compliance pack, Draft commercial terms, Other
• Are there any non-negotiable constraints or governance rules we must respect when designing the pilot and deployment?